Jazz Pharmaceuticals JAZZ Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's additional paid-in capital?
- Jazz Pharmaceuticals (JAZZ) reported additional paid-in capital of $4.24B in Q1 2026.
- How has Jazz Pharmaceuticals's additional paid-in capital changed year-over-year?
- Jazz Pharmaceuticals's additional paid-in capital increased by 8.1% year-over-year, from $3.93B to $4.24B.
- What is the long-term trend for Jazz Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's additional paid-in capital has grown at a 10.0% compound annual growth rate (CAGR), from $2.63B to $4.24B.
- What does additional paid-in capital mean?
- The total amount of money shareholders paid for shares above their nominal par value.
- How do you interpret additional paid-in capital?
- An increase typically signals equity financing activities or the issuance of stock-based compensation to employees.
- How does additional paid-in capital compare across companies?
- Standard for all public companies; high levels often correlate with frequent equity raises or aggressive stock-based compensation.